A potential treatment for COVID-19 patients that has been approved by Health Canada is seeing low uptake from the individual provinces due to various concerns. AbCellera’s banlanivimab was approved with multiple conditions attached in both Canada and the United States in November 2020. Company leadership says that when it is given to patients early in the course of illness it can reduce the likelihood of progression to severe disease. That said, it has seen very low use as several provinces have cited concerns, including unfavourable reviews from two expert panels as well as on-going uncertainty over whether the drug’s benefit outweighs its risk.